InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (6 ops.)
Browse the detailed record of transactions filed by SOFINNOVA PARTNERS, Partner, Sofinnova Partners. Insider active across 2 companies, notably SENSORION. Aggregated, 32 filings have been published. Total volume traded: €235.5m. The latest transaction was filed on 28 January 2026 (Souscription). Regulator: AMF. All data is accessible without signup.
Declarations32 total
€3m10,714,285 shares@ €0.2811.8% of flow
ActionEuronext Growth Paris
2026DD1091922·
US$116m950,000 shares@ US$122.40791.23% mcap39.2% of flow
American Depositary SharesNasdaq Global Market (US)
2026DD1089198·
€56m590,877 shares@ €94.1640.59% mcap18.8% of flow
American Depositary SharesNasdaq Global Market
2025DD1066576·
US$56m590,877 shares@ US$94.1640.59% mcap18.8% of flow
American Depositary SharesNasdaq Global Market
2025DD1066880·
US$17m270,000 shares@ US$64.005.8% of flow
American Depositary SharesNasdaq Global Market
2025DD1050946·
€1m5,882,353 shares@ €0.175.2% of flow
Actions à bons de souscription d'actionsEuronext Paris
2025DD1046658·
€200,000889,680 shares@ €0.22481.0% of flow
Actions à bons de souscription d'actionsEuronext Paris
2025DD1025162·
€750,0002,663,353 shares@ €0.28163.9% of flow
Actions à bons de souscription d'actionsEuronext Paris
2025DD1013140·
€987,9342,812,223 shares@ €0.35135.1% of flow
Actions à bons de souscription d'actionsEuronext Paris
2024DD1004364·
€2m5,063,291 shares@ €0.39510.4% of flow
Actions à bons de souscription d'actionsEuronext Paris
2024DD965281·
€1,000,0001,587,301 shares@ €0.633.9% of flow
ActionEuronext Growth Paris
2024DD960175·
€7m12,280,701 shares@ €0.5727.5% of flow
ActionEuronext Growth Paris
2024DD950579·
€2m5,224,660 shares@ €0.382810.4% of flow
ActionEuronext Paris
2024DD950181·
€69,733110,740 shares@ €0.62975.1% of flow
ActionEuronext Growth Paris
2024DD945371·
€2m3,038,279 shares@ €0.712211.3% of flow
Titre de créanceEuronext Paris
2023DD939161·
€14m1,200,000 shares@ €11.604.7% of flow
ActionNasdaq Global Market
2023DD934449·
US$14m1,200,000 shares@ US$11.604.7% of flow
ActionNasdaq Global Market
2023DD935816·
€2m21 shares@ €100,000.0010.9% of flow
Titre de créanceHors plateforme de négociation
2023DD925700·
€7m25,000,000 shares@ €0.2827.5% of flow
ActionEuronext Growth Paris
2023DD923626·
€10m1,535,000 shares@ €6.503.4% of flow
ActionEuronext Paris
2023DD887610·
€309,5201 shares@ €309,520.000.1% of flow
Titre de créanceHors plateforme de négociation
2022DD860017·
€5m584,000 shares@ €8.360.052% mcap1.6% of flow
ActionEuronext Paris
2022DD859590·
Ideal exit: 30 May 2023 (T+270)
US$2m138,880 shares@ US$14.3710.26% mcap16.6% of flow
ActionNASDAQ
2021DD783824·
Ideal exit: 26 Jun 2022 (T+270)
€8m261,865 shares@ €30.552.7% of flow
ActionEuronext Paris
2021DD765910·
€8m7,500,000 shares@ €1.0029.4% of flow
Obligations convertiblesEuronext Growth Paris
2021DD744035·
25 of 32 declarations
About SOFINNOVA PARTNERS
Sofinnova Partners is a leading European venture capital firm focused on life sciences. In that capacity, its name is closely linked to several public and growth-stage biotechnology companies, including Sensorion and Abivax, where Sofinnova Partners has acted as a key investor and strategic supporter. At Abivax, Sofinnova Partners has participated in major financing transactions that strengthened the company’s shareholder base and supported its long-term clinical development strategy. At Sensorion, the firm has also backed capital raises designed to accelerate the company’s pipeline in audiology and genetic medicine. As an investment partner, Sofinnova Partners is known for its expertise in financing, governance, syndication of capital rounds, and support for both listed and pre-IPO companies. Its activity spans the full development cycle of healthcare innovation businesses, from early-stage ventures to crossover rounds and public markets. The firm is particularly associated with identifying strong scientific teams, valuing differentiated therapeutic assets, and helping build credible equity-market trajectories for European biotech companies. Sofinnova Partners’ involvement in companies such as Abivax and Sensorion demonstrates its ability to combine industry insight, financial discipline, and a deep understanding of regulatory and clinical execution challenges. This profile makes it an influential player in the governance of healthcare innovation companies in Europe, often contributing at board level and providing strategic direction on growth, financing, and clinical development.
